Phycocyanin study for liver fibrosis and cirrhosis
Part of Digestive system clinical trials.
This trial tests if phycocyanin (a natural blue pigment from spirulina) can help protect the liver and slow damage from fibrosis or cirrhosis. It may be an option if you have stable liver disease and are looking for supportive therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with liver fibrosis or cirrhosis.
- You have not had any new acute illness or a major worsening of symptoms in the past 4 weeks.
- You are willing to take part and sign a consent form.
- You do not have severe other medical conditions or a history of serious mental illness that would interfere with treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests a treatment made from stem cells to see if it is safe and can help reduce scarring and improve liver function in people with liver cirrhosis. It focuses on patients with moderate liver disease (Child-Pugh Class B).
This trial tests if the blood thinner apixaban can prevent liver cirrhosis from getting worse in people with alcohol-related liver disease. It may help reduce the risk of serious complications like fluid buildup or bleeding.
This study tests whether eating more dietary fiber can improve outcomes for people with liver cirrhosis and high blood pressure in the liver (portal hypertension). If you have cirrhosis, adding fiber to your diet might help.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This study compares patients with advanced liver scarring (cirrhosis) to healthy controls to learn more about the condition. It may help researchers better understand and manage liver disease.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.